Drugs / BE CAR33 T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05942599 | Jul 2023 → Jun 2026 overdue | acute myeloid leukemia | Great Ormond Street Hospital for Children NHS Foundation Trust | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BE CAR33 T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05942599 ↗ |
| Known as | BE752TBTTBCAR33PBL | “Cryopreserved BE CAR33 T Cells (BE752TBTTBCAR33PBL)” NCT05942599 ↗ |
| Action | Deplete | “changed so they can kill leukaemia cells” NCT05942599 ↗ |
| Modality | Cell therapy | “These 'ready-made' CAR T cells” NCT05942599 ↗ |
| Route | Intravenous | “Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR33+ T cells/kg” NCT05942599 ↗ |